Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045877 · ClinicalTrials.gov registry record · Phase 2
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
A Phase 2 study, sponsored by Chiron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045877: Completed Phase 2 study, sponsored by Chiron Corporation.
NCT00045877 is a Phase 2 study that has completed, run by Chiron Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045877, a Phase 2 study, has completed, sponsored by Chiron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
Interventions
- DRUG Recombinant Human Interleukin-2 and Rituximab
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00045877 record still lists
NCT00045877 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Interleukin-2 and Rituximab is the first listed.
NCT00045877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045877 about?
NCT00045877 is a clinical study titled "Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments". The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
What is the current status of trial NCT00045877?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00045877?
The interventions under investigation include: Recombinant Human Interleukin-2 and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00045877?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.